1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
SVP & General Counsel
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
Following the vesting on 16 February 2021 of an award made on 6
September 2018 under the GlaxoSmithKline Deferred Investment Award
programme in lieu of a Share Value Plan award, Mr Ford will receive
a cash payment of $225,308 less applicable tax withholding in
respect of 6,320 notional American Depositary Shares.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$35.6500
|
6,320
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Waterhouse
|
|||
b)
|
Position/status
|
CEO of ViiV Healthcare
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Following the vesting on 16 February 2021 of an award made on 16
February 2015 under the GlaxoSmithKline Deferred Investment Award
programme in lieu of a Share Value Plan award, Ms Waterhouse will
receive a cash payment of £194,803.33 less applicable tax
withholding in respect of 15,302.697 notional Ordinary
Shares.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.7300
|
15,302.697
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
19, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|